<DOC>
	<DOCNO>NCT00360945</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give cisplatin together temozolomide work treat young patient malignant glioma .</brief_summary>
	<brief_title>Cisplatin Temozolomide Treating Young Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate ( complete partial response ) pediatric patient malignant glioma treat temozolomide cisplatin . Secondary - Identify genetic , metabolic , proteomic profile provide insight molecular pathway involve pathogenesis tumor . - Link genetic change clinical detail , histopathology , patient outcome , thereby develop biological basis diagnosis , prognosis , treatment monitoring . - Evaluate relapse-free survival 1 2 year patient treat diagnosis . - Evaluate duration clinical response patient treat relapse . - Study health status quality life patient . - Evaluate long-term toxicity therapeutic combination . - Evaluate ability magnetic resonance spectroscopy v CT scan predict response patient high-grade astrocytomas . OUTLINE : This multicenter , open-label , nonrandomized , parallel-group study . Patients stratify accord disease status ( newly diagnose v relapse ) . Patients newly diagnose disease stratify accord spread disease ( localize measurable v diffuse unmeasurable ) . - Stratum I ( newly diagnose disease ) : Patients receive CISTEM chemotherapy comprise cisplatin IV 3 hour day 1 oral temozolomide daily day 2-6 . Treatment repeat every 28 day 7 course . Patients achieve responsive stable disease 2 course receive 2 course CISTEM chemotherapy undergo radiotherapy 5 day week 6 week . After completion radiotherapy , patient may receive 3 course CISTEM chemotherapy total 7 course . - Stratum II ( relapsed disease ) : Patients receive CISTEM chemotherapy 7 course stratum I . Patients reach maximum dose allow cisplatin may receive oral temozolomide alone indefinitely . Tissue blood sample obtain baseline examine immunohistochemistry , fluorescent situ hybridization ( FISH ) , loss heterozygosity . The tumor tissue analyze p53 , MSH2 , MLH1 , MGMT . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 87 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 follow grade III grade IV malignant glial tumors* : Glioblastoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic oligoastrocytoma Anaplastic ganglioglioma Anaplastic mixed tumor Glial component essential NOTE : *Malignant glioma occur second primary malignancy allow Newly diagnose recurrent disease No malignant brain stem tumor Incompletely resect tumor No completely resect tumor Measurable evaluable disease conventional MRI PATIENT CHARACTERISTICS : Lansky performance status 40100 % Organ toxicity ≤ grade 2 Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Prothrombin ≥ 50 % Fibrinogen ≥ 1.5 g/L Creatinine normal age Creatinine ≤ 65 µmol/L ( 415 year age ) Creatinine ≤ 110 µmol/L ( 1520 year age ) Audiogram toxicity grade ≤ 2 ECG normal Negative pregnancy test Fertile patient must use effective contraception No severe lifethreatening infection No uncontrolled develop symptomatic intracranial hypertension PRIOR CONCURRENT THERAPY : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) radiotherapy patient relapse disease No prior cisplatin temozolomide No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
</DOC>